Diabetes
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Justo, P.
Right arrow Articles by Ortiz, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Justo, P.
Right arrow Articles by Ortiz, A.
Social Bookmarking
 Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Diabetes 54:2424-2429, 2005
© 2005 by the American Diabetes Association, Inc.

3,4-Dideoxyglucosone-3-ene Induces Apoptosis in Renal Tubular Epithelial Cells

Pilar Justo1, Ana Belén Sanz1, Jesús Egido1,2,3, and Alberto Ortiz1,2,3

1 Division of Nephrology and Hypertension, Fundación Jiménez Díaz, Madrid, Spain
2 Universidad Autónoma de Madrid, Madrid, Spain
3 Instituto Reina Sofía de Investigaciones Nefrológicas, Madrid, Spain

Diabetes complications are caused by hyperglycemia. Hyperglycemia results in increased concentrations of glucose degradation products. The study of peritoneal dialysis solution biocompatibility has highlighted the adverse effects of glucose degradation products. Recently, 3,4-dideoxyglucosone-3-ene (3,4-DGE) has been identified as the most toxic glucose degradation product in peritoneal dialysis fluids. Its role in renal pathophysiology has not been addressed. 3,4-DGE induces apoptosis in murine renal tubular epithelial cells in a dose- and time-dependent manner. Peak apoptosis is observed after 72 h of culture. The lethal concentration range is 25–50 µmol/l. 3,4-DGE results in Bax oligomerization, release of cytochrome c from mitochondria, activation of caspases-9 and -3, and Bid proteolysis. Apoptosis induced by 3,4-DGE is caspase dependent and could be prevented by the broad-spectrum caspase inhibitor zVAD-fmk (Z-Val-Ala-DL-Asp-fluoromethylketone) and by specific inhibitors of caspases-2, -8, and -9. However, caspase inhibition did not prevent eventual cell death. In contrast, antagonism of Bax by a Ku-70–derived peptide or antisense oligonucleotides prevented both apoptosis and cell death. In conclusion, 3,4-DGE promotes apoptosis of cultured renal parenchymal cells by a Bax- and caspase-dependent mechanism. A role for 3,4-DGE in diabetes complications in the kidney and in the modulation of residual renal function in peritoneal dialysis should be further explored.


Address correspondence and reprint requests to Alberto Ortiz, Unidad de Diálisis, Fundación Jiménez Díaz, Av Reyes Católicos 2, 28040 Madrid, Spain. E-mail: aortiz{at}fjd.es

Abbreviations: 3-DG, 3-deoxyglucosone; 3,4-DGE, 3,4-dideoxyglucosone-3-ene; DEVD-fmk, Z-Asp(OMe)-Glu(OMe)-Val-DL-Asp(OMe)-fluoromethylketone; IETD-fmk, Z-Ile-Glu(OMe)-Thr-Asp(OMe)-fluoromethylketone; LEHD-fmk, Z-Leu-Glu(OMe)-His-Asp(OMe)-fluoromethylketone; zVAD-fmk, Z-Val-Ala-DL-Asp-fluoromethyl-ketone


Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
Nephrol Dial TransplantHome page
A. Breborowicz, K. Pawlaczyk, A. Polubinska, K. Gorna, A. Wieslander, O. Carlsson, P. Tam, and G. Wu
Effect of peritoneal dialysis on renal morphology and function
Nephrol. Dial. Transplant., December 1, 2006; 21(12): 3539 - 3544.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 2005 by the American Diabetes Association.